Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash & Current Investments: 2018-2024

Historic Cash & Current Investments for Legend Biotech (LEGN) over the last 7 years, with Dec 2024 value amounting to $286.7 million.

  • Legend Biotech's Cash & Current Investments fell 9.88% to $278.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 46.60%. This contributed to the annual value of $286.7 million for FY2024, which is 77.57% down from last year.
  • Per Legend Biotech's latest filing, its Cash & Current Investments stood at $286.7 million for FY2024, which was down 77.57% from $1.3 billion recorded in FY2023.
  • Legend Biotech's Cash & Current Investments' 5-year high stood at $1.3 billion during FY2023, with a 5-year trough of $286.7 million in FY2024.
  • In the last 3 years, Legend Biotech's Cash & Current Investments had a median value of $971.6 million in 2022 and averaged $845.6 million.
  • As far as peak fluctuations go, Legend Biotech's Cash & Current Investments spiked by 419.42% in 2020, and later slumped by 77.57% in 2024.
  • Over the past 5 years, Legend Biotech's Cash & Current Investments (Yearly) stood at $433.0 million in 2020, then soared by 59.11% to $688.9 million in 2021, then spiked by 41.03% to $971.6 million in 2022, then spiked by 31.57% to $1.3 billion in 2023, then tumbled by 77.57% to $286.7 million in 2024.